Information  X 
Enter a valid email address

Dechra Pharm PLC (DPH)

  Print      Mail a friend       Annual reports

Tuesday 30 June, 2020

Dechra Pharm PLC

Total Voting Rights

RNS Number : 5274R
Dechra Pharmaceuticals PLC
30 June 2020


30 June 2020


Dechra® Pharmaceuticals PLC

(Dechra or the Company)

LEI: 213800J4UVB5OWG8VX82


Total Voting Rights



In conformity with DTR 5.6.1R, the Company notifies the market of the following:


As at the date of this announcement, the Company's issued share capital consists of 108,010,960 ordinary shares with a nominal value of 1 pence each (Ordinary Shares), with voting rights.  The Company does not hold any Ordinary Shares in Treasury.


Therefore, the total number of Ordinary Shares with voting rights is 108,010,960.


The above figure of 108,010,960 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.



For further information, please contact:

Dechra Pharmaceuticals PLC

Telephone number:  +44 (0) 1606 814730

Email: [email protected]



About Dechra

Dechra is a global veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: .



Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t